Department of Pathology, University of Pittsburgh Medical Centre, Pittsburgh, PA, USA.
Histopathology. 2022 Dec;81(6):696-714. doi: 10.1111/his.14713. Epub 2022 Jul 15.
Colorectal carcinoma is a leading cause of cancer-related death worldwide. There is significant prognostic heterogeneity in stages II and III tumours, necessitating the development of new biomarkers to more clearly identify patients at risk of disease progression. Recently, the tumour immune environment, particularly the type and quantity of T lymphocytes, has been shown to be a useful biomarker in predicting prognosis for patients with colorectal carcinoma. In this review, the significance of the immune response in colorectal carcinoma, including its influence on prognosis and response to therapy, will be detailed.
结直肠癌是全球癌症相关死亡的主要原因。在 II 期和 III 期肿瘤中，存在显著的预后异质性，因此需要开发新的生物标志物，以更清楚地识别有疾病进展风险的患者。最近，肿瘤免疫环境，特别是 T 淋巴细胞的类型和数量，已被证明是预测结直肠癌患者预后的有用生物标志物。在这篇综述中，将详细阐述免疫反应在结直肠癌中的意义，包括其对预后和对治疗反应的影响。
